

CLEAN COPY OF ALLOWED CLAIMS

Claim 32 A purified polypeptide comprising at least one T epitope from a liver-stage specific protein produced by *P. falciparum*, wherein the amino acid sequence of said T epitope is selected from the group of the amino acid sequences of SEQ ID NOS: 41, 45 and 46.

Claim 35 The polypeptide of claim 32, further comprising at least one B epitope from a liver-stage specific protein produced by *P. falciparum*.

Claim 39 A synthetic polypeptide comprising at least one T epitope from a liver-stage specific protein produced by *P. falciparum*, wherein the amino acid sequence of said T epitope is selected from the group of the amino acid sequences of SEQ ID NOS: 41, 45 and 46.

Claim 42 An immunogenic composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of *P. falciparum* in hepatic cells, wherein said T epitope is selected from the group of: the amino acid sequence of SEQ ID NOS: 19, 41, 42, 45 and 46.

Claim 43 An immunogenic composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of *P. falciparum* in hepatic cells, wherein said T epitope is selected from the group of: the amino acid sequence of SEQ ID NOS: 19, 41 and 45.

CLEAN COPY OF AMENDMENT TO SPECIFICATION

On page 1, line 1 of the specification:

This application is a divisional of Application Serial No. 08/426,625 filed on June 5, 1995 now US Patent 6,319,502, which is a divisional of Application Serial No. 08/098,327 filed on November 24, 1993 now US Patent 6,270,771, which is a national stage filing under 35 U.S.C. 371 of International Application No. PCT/FR92/00104 filed on February 5, 1992, which International Application was not published by the International Bureau in English.